Notch Promotes Radioresistance of Glioma Stem Cells

0301 basic medicine Cell Death Cell Survival Mice, Nude Dose-Response Relationship, Radiation 3. Good health Mice Phosphatidylinositol 3-Kinases 03 medical and health sciences Proto-Oncogene Proteins c-bcl-2 Antigens, CD Neoplastic Stem Cells Animals Humans Myeloid Cell Leukemia Sequence 1 Protein AC133 Antigen Amyloid Precursor Protein Secretases Enzyme Inhibitors Glioblastoma Peptides Proto-Oncogene Proteins c-akt Cell Proliferation Glycoproteins
DOI: 10.1002/stem.261 Publication Date: 2009-11-17T20:43:43Z
ABSTRACT
Abstract Radiotherapy represents the most effective nonsurgical treatments for gliomas. However, gliomas are highly radioresistant and recurrence is nearly universal. Results from our laboratory and other groups suggest that cancer stem cells contribute to radioresistance in gliomas and breast cancers. The Notch pathway is critically implicated in stem cell fate determination and cancer. In this study, we show that inhibition of Notch pathway with γ-secretase inhibitors (GSIs) renders the glioma stem cells more sensitive to radiation at clinically relevant doses. GSIs enhance radiation-induced cell death and impair clonogenic survival of glioma stem cells but not non-stem glioma cells. Expression of the constitutively active intracellular domains of Notch1 or Notch2 protect glioma stem cells against radiation. Notch inhibition with GSIs does not alter the DNA damage response of glioma stem cells after radiation but rather reduces Akt activity and Mcl-1 levels. Finally, knockdown of Notch1 or Notch2 sensitizes glioma stem cells to radiation and impairs xenograft tumor formation. Taken together, our results suggest a critical role of Notch signaling to regulate radioresistance of glioma stem cells. Inhibition of Notch signaling holds promise to improve the efficiency of current radiotherapy in glioma treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (79)
CITATIONS (427)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....